Morgan Stanley Bio Atla, Inc. Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
A detailed history of Morgan Stanley transactions in Bio Atla, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,910,144 shares of BCAB stock, worth $2.92 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,910,144
Previous 1,913,115
0.16%
Holding current value
$2.92 Million
Previous $4.71 Million
39.61%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BCAB
# of Institutions
88Shares Held
24.8MCall Options Held
140KPut Options Held
4.6K-
Soleus Capital Management, L.P. Greenwich, CT4.07MShares$6.22 Million1.14% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$4.25 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.1MShares$3.21 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.47MShares$2.26 Million0.62% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.24MShares$1.9 Million0.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $55.5M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...